Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.
The activity of a new organometallic compound, titanocendichloride, was evaluated in doxorubicin- and cisplatin-resistant human ovarian carcinoma cell lines in vitro. Titanocendichloride showed no cross resistance to doxorubicin in two multidrug resistant sublines of A2780. Furthermore, the cell line A2780 CP3, which is about 20-fold resistant to cisplatin was only 2.5-fold resistant to titanocendichloride, indicating a lack of cross resistance between the two metal compounds. These results were confirmed in vivo where titanocendichloride showed a much stronger inhibitory effect in cisplatin-resistant human ovarian carcinoma xenografts than cisplatin.
Department of Hematology/Oncology, University of Hannover Medical School, F.R.G.
A
A
Harstrick
H J
HJ
Schmoll
G
G
Sass
H
H
Poliwoda
Y
Y
Rustum
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014025:Titanium; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D004317:Doxorubicin; D014025:Titanium; C020528:titanocene dichloride; D002945:Cisplatin